MC
VRDN icon

Merck & Co’s Viridian Therapeutics VRDN Stock Holding History

Merck & Co’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.83M Hold
93,414
– – 0.52% 10
2025
Q4 		$2.91M Hold
93,414
– – 1.05% 8
2025
Q3 		$2.02M Hold
93,414
– – 0.88% 8
2025
Q2 		$1.31M Hold
93,414
– – 0.61% 9
2025
Q1 		$1.26M Hold
93,414
– – 0.77% 9
2024
Q4 		$1.79M Buy
+93,414
New +$2.03M 0.69% 8

Other funds holding VRDN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Merck & Co's VRDN Position: Q1 2026 in Review

Merck & Co held its Viridian Therapeutics (VRDN) position steady in Q1 2026 at 93,414 shares worth $1.83M. The position accounts for 0.52% of the portfolio, ranked #10.

Merck & Co first reported a position in VRDN in Q4 2024 and has held it in 6 quarters since. The position peaked at $2.91M in Q4 2025. 225 funds tracked by Wall St. Rank hold VRDN as of Q1 2026.

  • Merck & Co held 93,414 shares of Viridian Therapeutics worth $1.83M as of Q1 2026.
  • Merck & Co left its Viridian Therapeutics share count unchanged in Q1 2026.
  • Viridian Therapeutics made up 0.52% of Merck & Co's portfolio in Q1 2026, its #10 holding.
  • Merck & Co first reported a position in Viridian Therapeutics in Q4 2024 and has held it in 6 quarters since.
  • Merck & Co's Viridian Therapeutics position peaked at $2.91M in Q4 2025.
  • 225 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q1 2026.

Based on Merck & Co's 13F filing for Q1 2026, filed 13 May 2026.